3-(4-hydroxyphenyl)-4-isobutyl-1H-pyrrole-2,5-dione | 1040394-24-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-(4-hydroxyphenyl)-4-isobutyl-1H-pyrrole-2,5-dione
• 英文别名: norprenyl antrodin；3-(4-hydroxyphenyl)-4-(2-methylpropyl)pyrrole-2,5-dione
• CAS: 1040394-24-8
• 化学式: C₁₄H₁₅NO₃
• 分子量: 245.278
• InChiKey: BAZBYJXDEUDANE-UHFFFAOYSA-N

物化性质

• 沸点：
  444.0±45.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-甲基丁-2-烯基膦酰磷酸氢酯 、 3-(4-hydroxyphenyl)-4-isobutyl-1H-pyrrole-2,5-dione 在 recombinant O-prenyltransferase from Antrodia camphorata 作用下， 以 aq. buffer 为溶剂， 反应 12.0h， 以11.6%的产率得到3-isobutyl-4-{4-[(3-methyl-2-butenyl)oxy]phenyl}-1H-pyrrole-2,5-dione
  参考文献：
  名称：

  药用香樟樟中允许的邻戊二烯基转移酶对多种酚类化合物的酶促O-异戊烯化作用

  摘要：

  烯丙基化的化合物是在自然界中广泛分布的具有药理吸引力的天然产物。异戊二烯基转移酶（PTs）可以催化异戊二烯基团向芳族受体的转移，并增加天然产物的结构多样性和生物活性。在这项工作中，从台湾珍贵的香菇樟芝中发现了一种允许的邻戊二烯基转移酶AcaPT 。AcaPT对结构多样的药物样酚类化合物（包括Antrodins，类黄酮和香豆素）表现出强大的O-异戊二烯化能力。通过放大酶促合成，总共获得了23种O-异戊烯化产品。AcaPT可用作合成O的有效生物催化剂用于药物开发的异戊二烯基衍生物。

  DOI：

  10.1002/adsc.201901396
• 作为产物：
  描述：

  4-甲基-2-氧代戊酸 在 乙酸酐 、 三溴化硼 、 三乙胺 、 六甲基二硅氮烷 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 3-(4-hydroxyphenyl)-4-isobutyl-1H-pyrrole-2,5-dione
  参考文献：
  名称：

  Biomimetic Synthesis of Antrodia Maleimides and Maleic Anhydrides

  摘要：

  A simple and efficient biomimetic synthesis of Antrodia maleimides and maleic anhydrides, including the HCV protease inhibitor antrodin A, is described. The key step is a Perkin-type condensation performed under exceptionally mild conditions.

  DOI：

  10.3987/com-13-s(s)92

文献信息

• NOVEL COMPOUNDS FROM ANTRODIA CAMPHORATA
  申请人：Kuo Yueh-Hsiung

  公开号：US20100130584A1

  公开（公告）日：2010-05-27

  Compounds isolated from the fruiting body of A. camphorata in a solid culture or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds or pharmaceutically acceptable salts thereof.
• USE OF NOVEL COMPOUNDS FROM FRUITING BODY OF ANTRODIA CAMPHORATA FOR TREATING AN INFLAMMATORY DISORDER
  申请人：Kuo Yueh-Hsiung

  公开号：US20120149753A1

  公开（公告）日：2012-06-14

  Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of A. camphorata in a solid culture. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds and pharmaceutical compositions including the compounds or pharmaceutically acceptable salts thereof.
• PHARMACEUTICAL COMPOSITION FOR TREATING CANCER IN AN INDIVIDUAL SUBJECT SUFFERING CANCER
  申请人：MA SHEN KAI RUEI CO., LTD.

  公开号：US20170042912A1

  公开（公告）日：2017-02-16

  A pharmaceutical composition for treating cancer in an individual, comprising at least a pharmaceutically effective amount of a novel target HCC reversal signal substance, and a pharmaceutically acceptable ingredient comprising a vehicle, a carrier, a diluent or an excipient; in which the ratio among each component of the pharmaceutical composition may be adjustable depending on the type of cancer; wherein the novel target HCC reversal signal substance comprises at least one selected from the group consisting of antroquinonol (AQL), antrocinnamonin A (ACA), antroquinonol B (AQB), antroquinonol D (AQD), dehydroeburicoic acid (DEA), dehydrosulphurenic acid (DSA), zhankuic acid A (ZAA), zhankuic acid C (ZAC), antcin K (ANK), antcin C (ANC), and a mixture thereof.
• PHARMACEUTICAL COMPOSITION FOR TREATING COLORECTAL CANCER
  申请人：MA SHEN KAI RUEI CO., LTD.

  公开号：US20170189417A1

  公开（公告）日：2017-07-06

  The present invention provides a pharmaceutical composition for treating colorectal cancer in a subject in need thereof, which comprises a first agent comprising at least a Zhankuic acid D (ZhAD); and a second agent comprising at least an Antroquinonol B (AnQB); as well as each of them can be obtained from the extractions of a fruiting body or a mycelium of Antrodia camphorata wherein the first agent and the second agent shows synergistic effect for use in the treatment of colorectal cancer or to prevent or to reduce the risk of a colorectal cancer metastasizing, compared to administration of the first agent or the second agent alone.
• PHARMACEUTICAL COMPOSITION FOR TREATING LUNG CANCER
  申请人：MA SHEN KAI RUEI CO., LTD.

  公开号：US20170189418A1

  公开（公告）日：2017-07-06

  The present invention provides a pharmaceutical composition for treating lung cancer in a subject in need thereof, which comprises a first agent comprising at least a dehydroeburicoic acid (DeEA); and a second agent comprising at least an Anctin K(AnK); as well as each of them can be obtained from the extractions of a fruiting body or a mycelium of Antrodia camphorata wherein the first agent and the second agent shows synergistic effect for use in the treatment of lung cancer or to prevent or to reduce the risk of a lung cancer metastasizing, compared to administration of the first agent or the second agent alone.